Gubra A/S (CO:GUBRA) — Market Cap & Net Worth
Market Cap & Net Worth: Gubra A/S (GUBRA)
Gubra A/S (CO:GUBRA) has a market capitalization of $848.91 Million (Dkr5.43 Billion) as of June 24, 2026. Listed on the CO stock exchange, this Denmark-based company holds position #9769 globally and #46 in its home market, demonstrating a -8.89% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Gubra A/S's stock price Dkr332.20 by its total outstanding shares 16333032 (16.33 Million). Review Gubra A/S debt and liabilities to assess the company's total debt and financial obligations.
Gubra A/S Market Cap History: 2023 to 2026
Gubra A/S's market capitalization history from 2023 to 2026. Data shows growth from $319.43 Million to $848.91 Million (40.92% CAGR).
Gubra A/S Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Gubra A/S's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.50x
Gubra A/S's market cap is 0.50 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.78x
Gubra A/S's market cap is 0.78 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $319.43 Million | $205.00 Million | -$44.52 Million | 1.56x | N/A |
| 2024 | $1.59 Billion | $265.74 Million | -$36.50 Million | 6.00x | N/A |
| 2025 | $1.32 Billion | $2.64 Billion | $1.69 Billion | 0.50x | 0.78x |
Competitor Companies of GUBRA by Market Capitalization
Companies near Gubra A/S in the global market cap rankings as of June 24, 2026.
Key companies related to Gubra A/S by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #218 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #443 globally with a market cap of $63.67 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #571 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #218 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $468.42 |
| #443 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.67 Billion | $618.03 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €251.70 |
| #571 | Argen-X | BR:ARGX | $47.14 Billion | €813.00 |
Gubra A/S Historical Marketcap From 2023 to 2026
Between 2023 and today, Gubra A/S's market cap moved from $319.43 Million to $ 848.91 Million, with a yearly change of 40.92%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Dkr848.91 Million | -35.81% |
| 2025 | Dkr1.32 Billion | -17.07% |
| 2024 | Dkr1.59 Billion | +399.20% |
| 2023 | Dkr319.43 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 24th, 2026 the market cap of Gubra A/S was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $848.91 Million USD |
| MoneyControl | $848.91 Million USD |
| MarketWatch | $848.91 Million USD |
| marketcap.company | $848.91 Million USD |
| Reuters | $848.91 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Gubra A/S
Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green. The company offers preclinical contract research and development services within metabolic and fibrotic diseases for th… Read more